PROVECTUS BIOPHARMACEUTICALS, INC. Quarterly Entity Common Stock, Shares Outstanding from Q2 2011 to Q2 2024

Taxonomy & unit
dei: shares
Description
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
Summary
Provectus Biopharmaceuticals, Inc. quarterly Entity Common Stock, Shares Outstanding history and growth rate from Q2 2011 to Q2 2024.
  • Provectus Biopharmaceuticals, Inc. Entity Common Stock, Shares Outstanding for the quarter ending August 12, 2024 was 420M shares, a 0.09% increase year-over-year.
Entity Common Stock, Shares Outstanding, Quarterly (shares)
Entity Common Stock, Shares Outstanding, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q2 2024 420M +385K +0.09% Aug 12, 2024 10-Q 2024-08-13
Q1 2024 420M +25K +0.01% Mar 27, 2024 10-K 2024-03-28
Q3 2023 420M -25K -0.01% Nov 13, 2023 10-Q 2023-11-14
Q2 2023 420M +25K +0.01% Aug 14, 2023 10-Q 2023-08-14
Q1 2023 419M +50K +0.01% Mar 28, 2023 10-K 2023-03-30
Q3 2022 420M +100K +0.02% Nov 9, 2022 10-Q 2022-11-09
Q2 2022 419M +15.5M +3.83% Aug 10, 2022 10-Q 2022-08-11
Q1 2022 419M +15.9M +3.94% Mar 25, 2022 10-K 2022-03-29
Q3 2021 419M +18.5M +4.61% Nov 9, 2021 10-Q 2021-11-10
Q2 2021 404M +9.64M +2.45% Aug 12, 2021 10-Q 2021-08-12
Q1 2021 404M +12.9M +3.29% Feb 28, 2021 10-K 2021-03-02
Q3 2020 401M +12.4M +3.19% Nov 12, 2020 10-Q 2020-11-12
Q2 2020 394M +6.77M +1.75% Aug 11, 2020 10-Q 2020-08-12
Q1 2020 391M +5.97M +1.55% Mar 2, 2020 10-K 2020-03-05
Q3 2019 389M +3.96M +1.03% Nov 12, 2019 10-Q 2019-11-12
Q2 2019 388M +4.48M +1.17% Aug 6, 2019 10-Q 2019-08-08
Q1 2019 385M +5.83M +1.54% Feb 28, 2019 10-K 2019-03-07
Q3 2018 385M +13.9M +3.74% Nov 2, 2018 10-Q 2018-11-08
Q2 2018 383M +12.7M +3.44% Jul 31, 2018 10-Q 2018-08-07
Q1 2018 379M +14.1M +3.87% Mar 16, 2018 10-K 2018-03-23
Q3 2017 371M +127M +52% Nov 7, 2017 10-Q 2017-11-08
Q2 2017 370M +158M +74% Aug 7, 2017 10-Q 2017-08-09
Q1 2017 365M +160M +77.9% Mar 10, 2017 10-K 2017-03-31
Q3 2016 244M +39.3M +19.2% Nov 4, 2016 10-Q 2016-11-09
Q2 2016 213M +8.27M +4.04% Aug 5, 2016 10-Q 2016-08-09
Q1 2016 205M +19.1M +10.2% Mar 24, 2016 10-K 2016-03-30
Q3 2015 205M +24.3M +13.5% Sep 30, 2015 10-Q 2015-11-05
Q2 2015 205M +27.9M +15.8% Jun 30, 2015 10-Q 2015-08-06
Q1 2015 186M +12.8M +7.42% Mar 31, 2015 10-Q 2015-05-07
Q3 2014 180M +40.3M +28.8% Sep 30, 2014 10-Q 2014-11-06
Q2 2014 177M +48M +37.3% Jun 30, 2014 10-Q 2014-08-07
Q1 2014 173M +51.1M +41.8% Mar 31, 2014 10-Q 2014-05-08
Q3 2013 140M +26.3M +23.1% Sep 30, 2013 10-Q 2013-11-12
Q2 2013 129M +15.7M +13.9% Jun 30, 2013 10-Q 2013-08-08
Q1 2013 122M +11.1M +10% Mar 7, 2013 10-K 2013-03-14
Q3 2012 114M +4.06M +3.7% Sep 30, 2012 10-Q 2012-11-08
Q2 2012 113M +4.27M +3.93% Jun 30, 2012 10-Q 2012-08-08
Q1 2012 111M Mar 7, 2012 10-K 2012-03-14
Q3 2011 110M Sep 30, 2011 10-Q 2011-11-08
Q2 2011 109M Jul 18, 2011 10-Q 2011-08-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.